ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Omega-3 fatty acid stops known trigger of lupus

Print Page
Email Article

Two Alzheimer's Drugs Show Potential - U.S. Studies

  [ 282 votes ]   [ Discuss This Article ] • July 23, 2004

By Jon Hurdle

Two experimental Alzheimer's drugs have the potential to prevent or halt the progress of the brain-wasting disease, doctors said on Wednesday. Both focus on beta-amyloid, a protein that is suspected of causing Alzheimer's. It accumulates into the characteristic clogs called plaques that distinguish the brains of people who have died from Alzheimer's.

An estimated 4.5 million Americans have the disease, a number that is expected to grow to 16 million by 2050 as the baby boom generation ages. More than 15 million people globally have Alzheimer's.

In one study at Georgetown University Medical Center in Washington, 58 people with mild to moderate Alzheimer's disease (news - web sites) took a drug called Alzhemed or a placebo for three months, then for an additional 21 months. Alzhemed, made by Montreal, Canada-based Neurochem Inc., is a pill just beginning Phase III trials, the final stage before a company seeks approval from regulators for a new drug.

The study, reported at a meeting of Alzheimer's experts in Philadelphia, found a significant drop in the level of beta-amyloid among patients who took the drug and no change among those taking the placebo. The researchers also found Alzhemed in cerebral spinal fluid, which indicates it was finding its way to the brain where it is needed. The drug reduced the levels of beta-amyloid in the spinal fluid and was generally safe and well tolerated, the researchers found.

TRIAL SET TO EXPAND Among patients who began the trial with mild Alzheimer's, there was no further cognitive decline after 12 months of taking the drug, said Dr. Paul Aisen, who leads the study. There are now 26 patients who have taken the drug for 16 months, and 19 who have taken it for 20 months, Aisen told a news conference. He said the trial will now be expanded. "It will be a large, long trial that will provide a definitive answer on the efficacy of Alzhemed in inhibiting Alzheimer's," Aisen said.

In another study, Eli Lilly & Co. is trying to prevent beta-amyloid from forming in the first place. A trial of 37 healthy adults aged over 45 found blood levels of beta-amyloid were reduced after they took LY450139, an experimental drug designed to interfere with the formation enzymes called secretases, which generate beta-amyloid. The trial found reduced levels of beta-amyloid in the blood after the drug was administered. Higher doses produced a greater reduction. Although the drug was detected in cerebral spinal fluid, it did not reduce concentration of beta-amyloid in the fluid. Researchers need to know the most effective dose before starting a larger trial, said Dr. Eric Siemers of Eli Lilly.

Alzheimer's begins with mild memory loss but can quickly progress to destroy learning, memory and patients' ability to care for themselves. There is no cure and it is always fatal.

Source: Yahoo! news. (C) Reuters. All rights reserved.

Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map